Haemonetics (HAE) Stock Price, News & Analysis

+0.94 (+0.99%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
212,894 shs
Average Volume
454,235 shs
Market Capitalization
$4.86 billion
P/E Ratio
Dividend Yield
Price Target

Haemonetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
13.5% Upside
$108.67 Price Target
Short Interest
5.21% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.56mentions of Haemonetics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$289,372 Sold Last Quarter
Proj. Earnings Growth
From $4.60 to $5.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.97 out of 5 stars

Medical Sector

201st out of 922 stocks

Surgical & Medical Instruments Industry

28th out of 96 stocks

HAE stock logo

About Haemonetics Stock (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Stock Price History

HAE Stock News Headlines

Haemonetics Stock Up 10.9% YTD: Will the Rally Continue?
4 Analysts Assess Haemonetics: What You Need To Know
Haemonetics Q4 Profit Falls, But Beats Estimates - Update
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Supplies
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$117.56 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.31 billion
Cash Flow
$5.94 per share
Book Value
$18.90 per share


Free Float
Market Cap
$4.86 billion

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

HAE Stock Analysis - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price target for 2024?

4 brokerages have issued 1-year price targets for Haemonetics' stock. Their HAE share price targets range from $94.00 to $125.00. On average, they expect the company's share price to reach $108.67 in the next year. This suggests a possible upside of 13.5% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2024?

Haemonetics' stock was trading at $85.51 on January 1st, 2024. Since then, HAE shares have increased by 12.0% and is now trading at $95.74.
View the best growth stocks for 2024 here

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,240,000 shares, an increase of 9.8% from the March 31st total of 2,040,000 shares. Based on an average daily volume of 476,900 shares, the short-interest ratio is presently 4.7 days. Approximately 4.5% of the shares of the stock are short sold.
View Haemonetics' Short Interest

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our HAE earnings forecast

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) released its earnings results on Thursday, May, 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.02. The medical instruments supplier had revenue of $343 million for the quarter, compared to analysts' expectations of $329.53 million. Haemonetics had a trailing twelve-month return on equity of 22.25% and a net margin of 8.98%. The firm's revenue for the quarter was up 12.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.77 earnings per share.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY25 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of $4.45-$4.75 for the period, compared to the consensus estimate of $4.40. The company issued revenue guidance of $1.37-$1.41 billion, compared to the consensus revenue estimate of $1.37 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (13.14%), Vanguard Group Inc. (10.63%), Westfield Capital Management Co. LP (1.38%), Price T Rowe Associates Inc. MD (1.11%), Allspring Global Investments Holdings LLC (0.99%) and Allspring Global Investments Holdings LLC (0.99%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Stewart W Strong and William P Mr Burke.
View institutional ownership trends

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HAE) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners